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Datasets for the reporting of primary tumour in bone: recommendations from the
International Collaboration on Cancer Reporting (ICCR)
Background and objectives: Bone tumours are relatively
rare and, as a consequence, treatment in a centre with
expertise is required. Current treatment guidelines also
recommend review by a specialised pathologist. Here we
report on international consensus-based datasets for the
pathology reporting of biopsy and resection specimens

of bone sarcomas. The datasets were produced under
the auspices of the International Collaboration on Cancer Reporting (ICCR), a global alliance of major (inter-)
national pathology and cancer organisations.
Methods and results: According to the ICCR’s process
for dataset development, an international expert panel
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consisting of pathologists, an oncologic orthopaedic
surgeon, a medical oncologist, and a radiologist produced a set of core and noncore data items for biopsy
and resection specimens based on a critical review and
discussion of current evidence. All professionals
involved were bone tumour experts affiliated with tertiary referral centres. Commentary was provided for
each data item to explain the rationale for selecting it
as a core or noncore element, its clinical relevance,
and to highlight potential areas of disagreement or
lack of evidence, in which case a consensus position

was formulated. Following international public consultation, the documents were finalised and ratified, and
the datasets, including a synoptic reporting guide,
were published on the ICCR website.
Conclusion: These first international datasets for bone
sarcomas are intended to promote high-quality, standardised pathology reporting. Their widespread adoption will improve the consistency of reporting,
facilitate multidisciplinary communication, and
enhance comparability of data, all of which will help
to improve management of bone sarcoma patients.

Keywords: bone sarcoma, data management, data registration, dataset, guidelines, ICCR, structured report,
synoptic report

Introduction
Pathology reporting on cancer resection specimens
provides information that is essential for individual
patient management, used for clinical trials and
tissue-based research, and recorded in cancer registries. Given this central role of pathology data in
cancer care and research at both the individual and
population levels, standardised and structured pathology reporting is essential to ensure that the relevant
information is complete, unambiguous, and delivered
in a user-friendly format.
Evaluation of bone tumour biopsies is often perceived as highly challenging by pathologists because
of their rarity, the relatively high number of distinct
tumour subtypes (which often show overlapping histomorphology), and the requirement for clinicalradiological correlation to come to an accurate diagnosis. Moreover, surgical resection specimens can be
complex to evaluate/process due to the various anatomic locations that may be involved and the necessity
for
extensive
macroscopic
evaluation,
documentation, and correlation with imaging findings. Thus, for accurate diagnosis of bone tumours a
multidisciplinary approach is imperative. It is the
responsibility of the clinician or radiologist requesting
the pathological examination of a specimen to provide information to the pathologist that will assist
subsequent tissue processing, diagnostic evaluation,
and final interpretation. The use of a standardised
pathology requisition/request forms including a
checklist of important clinical information is strongly
encouraged to help ensure that these data are provided by submitting clinicians. It is the responsibility
of the pathologist to verify that all radiological and

clinical information essential to make a diagnosis is
available to guarantee that the final diagnosis is
made within the appropriate clinical/imaging context.
This is often achieved through discussion at a multidisciplinary tumour board meeting.
Several worldwide organisations such as the College of American Pathologists (CAP) and the Royal
College of Pathologists (RCPath) have independently
developed datasets for pathology reporting on bone
sarcoma.1–3 The International Collaboration on Cancer Reporting (ICCR) coordinates the production of
evidence-based international pathology reporting
datasets that have a consistent style and contain all
the parameters needed to guide patient management.
The ICCR is a collaboration of multiple pathology
organisations and has alliances with international
cancer organisations, including the International
Agency for Research on Cancer (IARC), Union for
International Cancer Control (UICC), and American
Joint Committee on Cancer (AJCC). The ICCR datasets
are freely available from the ICCR website (http://
www.iccr-cancer.org).
Here we report on the development of datasets for
the pathology reporting of primary bone sarcomas
(both biopsy and resection specimens), discuss the
rationale for the inclusion of data items, and propose
a consensus position in areas of controversy and
where there is limited evidence to assist pathologists
in their diagnostic practice.

Materials and Methods
The ICCR has developed a set of standardised operating procedures for the process of dataset development
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and has also defined the selection process, roles, and
responsibilities of the chair, expert panel members,
the ICCR Dataset Steering Committee representative
(s) on the panel, ICCR Series Champion, and the project manager (http://www.iccr-cancer.org/datasets/
dataset-development). The ICCR Series Champion provided guidance and support to the Chair of the Dataset Authoring Committee (DAC) regarding ICCR
standards and ensured harmonisation across the bone
and soft-tissue suite of datasets. An international
expert panel consisting of pathologists, an oncologic
orthopaedic surgeon, a medical oncologist, and a
radiologist was established. Initial draft documents
were produced by the Project Manager and chair
after assessment of core and noncore data items
within existing international datasets for bone sarcomas. These drafts were circulated to the Dataset
Authoring Committee (DAC) and individual dataset
items were discussed at a coordinated series of teleconferences. Subsequently, an agreed version of the
revised datasets was posted for open international
consultation on the ICCR website for a period of
2 months. All comments received were subsequently
discussed by the DAC and, where there was universal
agreement from DAC members, resultant changes
were incorporated into the datasets. Final versions
were ratified by the ICCR Dataset Steering Committee
prior to publication. All ICCR datasets, including
these on bone sarcomas, are freely available worldwide at the ICCR website at www.iccr-cancer.org/
datasets.

Results
SCOPE

The ICCR has developed two separate datasets for the
pathology reporting of biopsy and resection specimens
of primary bone tumours. Ewing sarcoma and related
round-cell sarcomas arising in bone are also covered
in these datasets. Some types of soft-tissue sarcoma
may on rare occasion arise primarily in bone and
should be reported using the primary tumour in bone
datasets, rather than the soft-tissue sarcoma datasets.
If biopsies are taken from multiple tumour nodules at
different sites, these should be documented separately.
Haematologic malignancies and metastatic specimens
were excluded from these datasets.
CORE ELEMENTS

3

These elements will either have evidentiary support
at Level III-2 or above (based on prognostic factors in
the National Health and Medical Research Council
(NHMRC) levels of evidence4). The summation of all
core elements is considered the minimum reporting
standard.
A summary of the core elements for the biopsy and
resection datasets is outlined in Tables 1 and 2,
respectively, and each is described in further detail
below.
NEOADJUVANT THERAPY

For resection specimens, information about neoadjuvant treatment is essential for proper interpretation of
the microscopic findings and accurate pathological
diagnosis. Preoperative radiation and/or other therapy may have a profound effect on the morphology
of both the cancer and benign tissue. Knowledge of
such prior therapy may help to interpret changes
such as necrosis, cellular atypia, and inflammatory
infiltrates. For this reason, information regarding any
prior therapy is important for the accurate assessment of bone specimens. Different scoring systems are
being used and are discussed under ‘Response to
neoadjuvant therapy’. For example, the use of denosumab in giant-cell tumour of bone induces bone formation and reduces the number of multinucleated
osteoclast-like giant cells within the lesion; therefore,
this information is crucial for diagnostic interpretation. Also, previous embolisation may cause areas of
necrosis. Moreover, neoadjuvant use of many novel
therapies (such as tyrosine kinase inhibitors or
immunotherapy) may result in histological effects and
need to be fully disclosed.

Table 1. Core and noncore elements for the pathology
reporting of primary tumour in bone biopsy specimens
Core

Noncore

Imaging findings

Clinical information

Operative procedure
• Type

Operative procedure
• Number of cores

Histological tumour type

Biopsy handling

Histological tumour grade

Necrosis

Ancillary studies

Lymphovascular invasion

Core elements are those that are essential for the clinical management, staging, or prognosis of the cancer.
! 2022 The Authors. Histopathology published by John Wiley & Sons Ltd., Histopathology
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Table 2. Core and noncore elements for the pathology
reporting of primary tumour in bone resection specimens
Core

Noncore

Neoadjuvant therapy
• Type

Clinical information

Imaging findings

Neoadjuvant therapy
• Included in clinical trial

Operative procedure

Tumour dimensions
• Additional dimensions

Anatomical site

Lymphovascular invasion

Tumour site

Margin status
• Type of tissue of closest margin
• Distance of tumour to osteotomy
(if not the closest margin)

Tumour laterality

Lymph node status

Tumour dimensions
• Largest diameter
• Presence of skip
metastases

Coexistent pathology

Histological tumour type

Pathological staging

Histological tumour grade
Microscopic extent
of invasion
Margin status
• R0
• R1
• R2
• Distance to and
localisation of
closest margin
Ancillary studies

IMAGING FINDINGS

Correlation between histologic and radiologic findings
is critical in the diagnosis of bone tumours. Ideally,
every case should be discussed in a multidisciplinary
conference or the pathologist should have at least
access to the imaging findings when evaluating a
biopsy. This is the main reason imaging findings are
considered a core element in bone tumour evaluation.
For instance, aggressive features identified radiographically (permeative/moth-eaten growth, cortical
destruction, soft tissue extension, type of periosteal
reaction) should be mentioned here, as well as multifocality, evidence of matrix deposition, presence of
fluid–fluid levels, etc. For instance, in cartilaginous
tumours in the phalanx or in Ollier disease, the distinction between benign and malignant may depend

solely on whether there is cortical destruction, which
may be impossible to evaluate on biopsy or fragmented curettage specimens alone. Therefore, these
diagnoses cannot be made without radiological correlation. The presence of fracture should always be documented, as it may alter the morphological features
and, in some instances, simulate aggressive features,
such as host bone entrapment. As the histological
alterations caused by the fracture change over time,
it is important to know the time frame between fracture and biopsy. Finally, certain bone tumours (cartilaginous tumours, vascular tumours) tend to occur
multifocally, and this information is also helpful for
the pathologist. The histological diagnosis should
always be correlated with the radiological diagnosis
and one should always be cautious when there is a
discrepancy between radiological and histological
findings. Multidisciplinary discussion is essential, and
repeat biopsy should be considered if differences of
opinion are not resolved.
It is important to know the exact tumour site
within the bone, since the histological differential
diagnosis will differ between intramedullary tumours
and those arising primarily at the bone surface. Also,
some tumours are almost exclusively found in the
epiphyseal region (e.g. clear-cell chondrosarcoma,
giant-cell tumour of bone, chondroblastoma), while
others preferentially affect the metaphysis (osteosarcoma) or involve also the diaphysis (Ewing sarcoma,
adamantinoma). Moreover, primary soft-tissue sarcomas may arise adjacent to and even invade bone,
while primary bone sarcomas may have an extensive
soft-tissue component. In these cases, radiological
information is required to decide whether the tumour
originates primarily from bone or soft tissue.
It is also important for the pathologist to be aware
of the radiological differential diagnosis when evaluating bone resection specimens. The presence of a
pathologic fracture may influence histological evaluation and should be documented. Certain bone
tumours (cartilaginous tumours, vascular tumours)
tend to occur multifocally, and skip metastases can
be present. This is important information for the
pathologist when working up the resection specimen.
Finally, the radiological response evaluation should
be recorded after neoadjuvant therapy.
ANATOMICAL SITE

For biopsy specimens, the anatomical site should be
documented by the radiologist and reported under
‘Imaging findings’. Recording the anatomical site of
the tumour is important, since certain bone tumours
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have predilections to arise in specific bones and not
others, and/or there is a strong association between
anatomic site and patient outcome. The latter is especially true for cartilaginous tumours; as a consequence, the World Health Organization (WHO)
Classification of Tumours, Soft Tissue and Bone
Tumours (5th edition, 2020)5 distinguishes between
atypical cartilaginous tumour and chondrosarcoma
grade 1, depending on whether the tumour is located
in the appendicular or axial skeleton, respectively.
When arising at appendicular sites (the long and
short tubular bones), these tumours behave in a
locally aggressive manner and do not metastasize.
Therefore, they can be treated locally and should not
be classified as having full malignant potential. The
term ‘atypical cartilaginous tumour’ is thus preferred
for cartilaginous tumours involving the long and
short tubular bones. In contrast, the term ‘chondrosarcoma, grade 1’ is used for histologically similar
tumours of the axial skeleton, including the pelvis,
scapula, and skull base (flat bones)―reflecting the
poorer clinical outcome and the necessity for more
aggressive treatment of these tumours at these sites.
It should be noted that the definition of axial versus appendicular is not universally accepted; while
the 2020 WHO Classification5 categorizes the scapula and skull base as part of the axial skeleton, the
UICC6/AJCC7 TNM 8th editions include these sites
with the appendicular skeleton. Here we consider
the scapula and skull base to be part of the axial
skeleton.
TUMOUR SITE

For biopsy specimens, the exact tumour site within
the bone should be documented by the radiologist
and reported under ‘Imaging findings’.
TUMOUR LATERALITY

For biopsy specimens, laterality should be documented by the radiologist or clinician and is reported
under ‘imaging findings’. Tumour laterality is a core
element.

5

cannot be assessed, such as for discontinuous
tumour, it is important to note this and record the
volume of tumour if possible. If biopsies are taken
from multiple tumour nodules at different sites, these
should be documented separately.
When reporting the gross evaluation of a bone
resection specimen, the pathologist should measure
the size of the tumour on the resection specimen in
at least its largest linear dimension (core element),
but preferably in three dimensions (noncore element),
as this is important in estimating tumour volume.
OPERATIVE PROCEDURE

This element includes the type and intent of the operative procedure, independent of the final margin
assessment by the pathologist. On the rare occasion
that lymph nodes are included with the specimen,
these should be listed under ‘other’. Metastasectomy
specimens can also be listed under ‘other’.
HISTOLOGICAL TUMOUR TYPE

Histologic diagnosis is based on the WHO classification
of soft tissue and bone tumours, 5th edition, 2020
(Table 3). The diagnosis is usually made on biopsy
before resection. In some cases, the biopsy is suboptimally targeted on the area(s) of interest or affected by
the surgical process, leaving the pathologist with tissue
that can be underrepresentative or misrepresentative
of the lesion based on the imaging studies. For some
entities, more sophisticated testing (e.g. molecular
analysis) may be required to achieve an accurate diagnosis, but the small tissue size, tissue processing issues,
or suboptimal targeting of biopsy materials may preclude ancillary diagnostic testing. The pathologist
should specify any and all limitations of the tissue sample that prevent achieving an optimal pathologic diagnosis. In addition, comments can be made in case the
diagnosis on biopsy is uncertain for reasons other than
limitations of the material or when there remains a differential diagnosis. When reporting resection specimens, a comment should be included if the final
diagnosis based on the resection specimen is discordant
with the previous diagnosis on the biopsy.

TUMOUR DIMENSIONS

For biopsies, the size of the largest tumour nodule
should be documented by the radiologist based on
imaging, preferably in three dimensions, as this is
important to evaluate the tumour volume; in the
dataset this will be reported under ‘imaging findings’.
In cases where the radiological tumour dimensions

HISTOLOGICAL TUMOUR GRADE

In bone sarcomas, the histotype primarily determines
histologic grade (based on the 2020 WHO Classification5), with only very few exceptions. Bone sarcomas
in which the grade is determined by histotype are
outlined in Table 4.

! 2022 The Authors. Histopathology published by John Wiley & Sons Ltd., Histopathology
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Table 3. World Health Organization classification of intermediate and malignant bone tumours and undifferentiated
small round-cell sarcomas5
Descriptor

ICD-O codesa

9222/1

Malignant
9250/3

Malignant
Conventional chordoma

Malignant
Chondrosarcoma, grade 1

9222/3b

Chondrosarcoma, grade 2

9220/3

Chondrosarcoma, grade 3

9220/3

Periosteal chondrosarcoma

9221/3

Clear cell chondrosarcoma

9242/3

Mesenchymal chondrosarcoma

9240/3

Dedifferentiated chondrosarcoma

9243/3

9370/3

Chondroid chordoma
Poorly differentiated chordoma

9370/3

Dedifferentiated chordoma

9372/3

Descriptor

ICD-O codesa

Other mesenchymal tumours of bone
Malignant
Adamantinoma of long bones

9261/3

Dedifferentiated adamantinoma

Osteogenic tumours
Malignant
Low-grade central osteosarcoma

9187/3

Osteosarcoma

9180/3

Conventional osteosarcoma
Telangiectatic osteosarcoma
Small cell osteosarcoma
Parosteal osteosarcoma

9192/3

Periosteal osteosarcoma

9193/3

High-grade surface osteosarcoma

9194/3

Secondary osteosarcoma

9184/3

Fibrogenic tumours
Malignant
8810/3

Vascular tumours of bone
Malignant
Epithelioid haemangioendothelioma NOS

9133/3

Angiosarcoma

9120/3

Leiomyosarcoma NOS

8890/3

Pleomorphic sarcoma, undifferentiated

8802/3

Haematopoietic neoplasms of bone
Plasmacytoma of bone

9731/3

Malignant lymphoma, non-Hodgkin, NOS

9591/3

Hodgkin disease NOS

9650/3

Diffuse large B-cell lymphoma NOS

9680/3

Follicular lymphoma NOS

9690/3

Marginal zone B-cell lymphoma NOS

9699/3

T-cell lymphoma NOS

9702/3

Anaplastic large cell lymphoma NOS

9714/3

Malignant lymphoma, lymphoblastic, NOS

9727/3

Burkitt lymphoma NOS

9687/3

Langerhans cell histiocytosis NOS

9751/1

Langerhans cell histiocytosis, disseminated

9751/3

Erdheim–Chester disease

9749/3

Rosai–Dorfman disease
Undifferentiated small round cell sarcomas

Osteoclastic giant cell–rich tumours
Intermediate (locally aggressive, rarely metastasizing)
Giant cell tumour of bone

ICD-O codesa

Notochordal tumours

Intermediate (locally aggressive)

Fibrosarcoma NOS

Descriptor

Giant-cell tumour of bone, malignant

Chondrogenic tumours

Atypical cartilaginous tumour

Table 3. (Continued)

9250/1

Ewing sarcoma

9364/3

Round cell sarcoma with
EWSR1–non-ETS fusions

9366/3b
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Table 3. (Continued)
Descriptor

ICD-O codesa

CIC-rearranged sarcoma

9367/3b

Sarcoma with BCOR genetic alterations

9368/3b

© World Health Organization/International Agency for Research
on Cancer. Reproduced with permission.
a
These morphology codes are from the International Classification
of Diseases for Oncology, third edition, second revision (ICD-O3.2). Behaviour is coded /0 for benign tumours; /1 for unspecified,
borderline, or uncertain behaviour; /2 for carcinoma in situ and
grade III intraepithelial neoplasia; /3 for malignant tumours, primary site; and /6 for malignant tumours, metastatic site.
b
Codes marked with an asterisk were approved by the International Agency for Research on Cancer/World Health Organization
Committee for ICD-O at its meeting in January 2020. Incorporates
all relevant changes from the 5th Edition Corrigenda October
2020.

MICROSCOPIC EXTENT OF INVASION

For correlation with imaging findings, histological
evidence of permeative growth, cortical invasion, and
destruction or soft tissue extension should be recorded
when reporting resection specimens. This is facilitated
when gross examination is aligned with the radiological imaging. Thus, preferably radiologic images
should be available when processing specimens.
RESPONSE TO NEOADJUVANT THERAPY

The response to preoperative chemotherapy is of
prognostic value, especially in Ewing sarcoma and
osteosarcoma, and needs to be evaluated in a standardised way when reporting resection specimens. At
least one complete central slab of tumour through its
largest dimension should be submitted for histological
evaluation. Additional sections can be taken from the
remaining two hemispheres of the specimen, especially near the periosteum and/or areas of soft tissue
extension. The amount of remaining viable tumour
cells should be estimated on each histological slide to
obtain an average score reflecting the overall percentage of response. Response does not always consist of
necrosis; very often, extensive fibrosis and calcification can be seen, which is also considered response.
In osteosarcoma, a cutoff of 10% viable tumour cells
(or 90% or more response consisting of tumour
necrosis, fibrosis, and calcification) is used to indicate
a good response.9 For Ewing sarcoma, the cutoff is
less well defined. Albergo et al. (2016) recently
showed that a 100% response was optimal to define
a good tumour response in Ewing sarcoma.10 In

7

earlier reports (the Bologna system11 as well as the
van der Woude scoring system12), a good response
was defined as the percentage of necrosis of the
microscopic tumour mass between 90% and 100%.
In the literature, different cutoffs are used to evaluate
chemotherapy-induced necrosis.13–16
MARGIN STATUS

Most features relating to the margin status of resection specimens are core (Table 2). There is no generally accepted approach for reporting bone tumour
margins. If margins are involved, a distinction is
often made between microscopic involvement (R1)
and resections in which it is evident macroscopically
that the tumour has been incompletely resected (R2).
In case of negative margins (R0), the minimum that
should be documented is the distance of the tumour
to the closest margin. Some guidelines recommend
that all margins <20 mm should be documented in
terms of depth and the tissue comprising each that is
<20 mm (e.g. fascia, periosteum, epineurium, vascular sheath).
ANCILLARY STUDIES

All immunohistochemical stainings and molecular
tests that contributed to the diagnosis should be documented. For instance, for Ewing sarcoma and other
round-cell sarcomas, lymphoma, adamantinoma, and
chordoma, these ancillary studies (immunohistochemical and/or molecular) are critical.
NONCORE ELEMENTS

Noncore elements are those which were unanimously
agreed by the committee to be included in the dataset
but are not supported by NHMRC level III-2 evidence.4 These elements may be clinically important
and recommended as good practice but are not yet
validated or regularly used in patient management. A
summary of the noncore elements for each of the
datasets is outlined in Tables 1 and 2 and each is
described below.
CLINICAL INFORMATION

For accurate diagnosis of bone tumours, a multidisciplinary approach is imperative. It is the responsibility
of the clinician or radiologist requesting the pathological examination of a specimen to provide information
to the pathologist that will have an impact on the diagnostic process or affect its interpretation. The use of a
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Table 4. Bone sarcomas in which grade is determined by
histotype
Grade 1(low-grade)

• Low-grade central osteosarcoma
• Parosteal osteosarcoma
• Clear cell chondrosarcoma

Grade 2
(intermediate-grade)

• Periosteal osteosarcoma

Grade 3 (high-grade)
• Osteosarcoma (conventional,
telangiectatic, small cell, secondary,
high-grade surface)
• Undifferentiated high-grade
pleomorphic sarcoma
• Ewing sarcoma and BCORrearranged sarcoma
• Dedifferentiated chondrosarcoma
• Mesenchymal chondrosarcoma
• Dedifferentiated chordoma
• Poorly differentiated chordoma
• Angiosarcoma
Variable

Not applicable

• Conventional chondrosarcoma
(grade 1–3 according to Evans)5,8
• Leiomyosarcoma of bone
(Grade 1–3 no established grading
system)
• Low- and high-grade malignancy
may occur in giant cell tumour
of bone
• Adamantinoma and conventional
chordoma

standard pathology requisition/request form including
a checklist of important clinical information is strongly
encouraged to help ensure that this information is provided by the clinicians with the specimen.
It is also the responsibility of the pathologist to verify that all radiological and clinical information essential to make a diagnosis is available to guarantee that
the final diagnosis is made within the appropriate
clinical/imaging context. This is often achieved
through discussion at a multidisciplinary tumour
board meeting.
BIOPSY HANDLING

Core needle biopsy is often performed under computed tomography (CT) or ultrasound guidance with
all imaging studies available for review during the
planning and execution of the procedure. Preferably a
minimum of three cores are submitted for diagnosis.
A frozen section can be performed on a representative
selection of cores or the tissue obtained at open
biopsy, to evaluate whether the biopsy has yielded

adequate tissue for diagnosis. Adequacy may also be
determined by cytological rapid on-site evaluation
(ROSE); the advantage of ROSE is that the biopsy core
evaluated remains almost entirely intact, preserving
tissue for other ancillary testing. Moreover, a provisional diagnosis can sometimes be given, and based
on the results the remaining tissue can be triaged for
further work-up. Bone tumours need decalcification
when formalin-fixed and paraffin-embedded (FFPE),
which, depending on the type of decalcification used,
may severely hamper the use of ancillary techniques.
Decalcification should optimally be performed with
solutions that preserve RNA and DNA, or a representative core should be kept frozen or embedded in
paraffin without prior decalcification, to allow for
molecular testing. Acid-based decalcification (other
than EDTA) should therefore be avoided if frozen tissue is unavailable.
NECROSIS

Necrosis in biopsy specimens where the patient has
not received neoadjuvant treatment should be documented, especially if necrosis is abundant, hampering
microscopic evaluation of the tumour.
LYMPHOVASCULAR INVASION

Lymphovascular invasion (LVI) is extremely rare in
bone tumours. However, it is important to report if
identified in the specimen.
MARGIN STATUS

In addition to documentation of involvement of margins (R0, R1, R2, distance of tumour from closest
margin and localisation of the closest margin) which
are considered core, some additional features of margin status are noncore (Table 2). The type of tissue
comprising the resection margin could also be
recorded (e.g. pseudocapsule, loose fibrous/fibroadipose tissue, bone, skeletal muscle, dense regular connective tissue fascia/aponeurosis/periosteum/vascular
sheath/perineurium) since bone and fascia may be
more robust marginal tissues than other tissue types.
In addition, the distance to the closest osteotomy
margin could also be recorded even if it is not the
closest margin.
LYMPH NODE STATUS

Lymph nodes are very rarely submitted or found with
bone specimens and it is not necessary to undertake
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an exhaustive search for nodes in the specimen.
Although regional lymph node metastasis is very rare
in adult bone sarcomas, its presence has prognostic
importance and it is important to report.
COEXISTENT PATHOLOGY

If present, the pathologist should report other abnormalities that are relevant for the diagnosis and any other
significant pathologic finding, even if unrelated or not
directly relevant. For instance, the presence of precursor
lesions for chondrosarcoma, such as multiple enchondromas, osteochondromas, or the presence of synovial
chondromatosis, should be documented. Paget disease,
osteonecrosis, or bone infarction may be seen in association with a secondary sarcoma. The presence of a pathologic fracture may influence the histological evaluation
and should be documented. Other unrelated findings
may include vasculitis, infection, coexistent chronic
lymphocytic leukaemia (CLL), or incidental/unexpected
metastatic carcinoma in the same specimen.
PATHOLOGICAL STAGING

It is important that pathologists document the
required parameters for tumour staging (according to
UICC6 or AJCC7 8th edition Staging Systems) in their
reports. Ultimately, the final stage will be determined
by the treating physician or by the multidisciplinary
team, which will take both the pathological and
imaging findings into account.

Discussion
Herein the construction and content of datasets for
the pathology reporting of biopsy and resection specimens of primary bone sarcomas internationally
agreed upon by a multidisciplinary group of bone
tumour experts working in tertiary referral centres
for bone sarcoma are reported. The current evidence
was considered and, where lacking, a panel consensus was reached. Data from the relevant medical literature, including the 5th edition of the WHO
Classification5 as well as other existing published
guidelines, were considered.1–3
The use of standardised reporting templates varies
widely. Some pathologists may not engage a standardised template if it is laborious and time-consuming, and
lacks the flexibility desired for providing a more nuanced
description of the differential diagnosis.17 A survey of
pathologists demonstrated that only 44% agreed that
standardised reporting facilitates reporting of an
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accurate diagnosis.17 However, it is well established that
structured pathology reporting ensures a more complete
diagnosis and, as a consequence, improved treatment
decisions and patient outcomes.18–20 Moreover, structured standardised reporting will accommodate cancer
registries and facilitate future large-scale artificial
intelligence-based studies. Standardised reporting is
essential for machine actionability, i.e, the capacity of
computational systems to find, access, interoperate, and
reuse data with minimal human intervention.21,22
These so-called FAIR principles (Findable, Accessible,
Interoperable, and Reusable) are especially important
for rare cancers such as bone sarcomas, where collaboration in research is often required to achieve significant
numbers of patients for meaningful statistical analysis.
Worldwide standardised reporting is the first step
towards FAIR data registration and stewardship and
may enable future distributed machine-learning
approaches for rare bone sarcomas,23 where local databases are connected across institutions and countries
without the necessity for patient data ever to leave the
institute of healthcare provision.23 This will unlock
research opportunities that are currently prohibited by
differences in registration, noncompatibility of information systems, and privacy and regulatory concerns.23
The support for standardised reporting can be improved
when it is supported by all multidisciplinary team members, when compatibility with other information systems is assured, and when incorporated in speech
recognition systems.17
In conclusion, we propose here two international
datasets for standardised reporting in bone sarcoma
care to improve the diagnosis, treatment, and outcome
for these patients and to facilitate future machinebased learning approaches for these rare sarcomas.
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